VDAC Modulation of Cancer Metabolism: Advances and Therapeutic Challenges.
VDAC Modulation of Cancer Metabolism: Advances and Therapeutic Challenges.
复制标题
VDAC对癌症代谢的调节:进步和治疗挑战。
DOI:
10.3389/fphys.2021.742839
复制
发表时间:
2021
影响因子:
4
通讯作者:
Maldonado EN
中科院分区:
文献类型:
--
作者:
Heslop KA;Milesi V;Maldonado EN
Most anionic metabolites including respiratory substrates, glycolytic adenosine triphosphate (ATP), and small cations that enter mitochondria, and mitochondrial ATP moving to the cytosol, cross the outer mitochondrial membrane (OMM) through voltage dependent anion channels (VDAC). The closed states of VDAC block the passage of anionic metabolites, and increase the flux of small cations, including calcium. Consequently, physiological or pharmacological regulation of VDAC opening, by conditioning the magnitude of both anion and cation fluxes, is a major contributor to mitochondrial metabolism. Tumor cells display a pro-proliferative Warburg phenotype characterized by enhanced aerobic glycolysis in the presence of partial suppression of mitochondrial metabolism. The heterogeneous and flexible metabolic traits of most human tumors render cells able to adapt to the constantly changing energetic and biosynthetic demands by switching between predominantly glycolytic or oxidative phenotypes. Here, we describe the biological consequences of changes in the conformational state of VDAC for cancer metabolism, the mechanisms by which VDAC-openers promote cancer cell death, and the advantages of VDAC opening as a valuable pharmacological target. Particular emphasis is given to the endogenous regulation of VDAC by free tubulin and the effects of VDAC-tubulin antagonists in cancer cells. Because of its function and location, VDAC operates as a switch to turn-off mitochondrial metabolism (closed state) and increase aerobic glycolysis (pro-Warburg), or to turn-on mitochondrial metabolism (open state) and decrease glycolysis (anti-Warburg). A better understanding of the role of VDAC regulation in tumor progression is relevant both for cancer biology and for developing novel cancer chemotherapies.
登录
查看更多内容
影响因子:
5.9
作者:
Brahimi-Horn MC;Giuliano S;Saland E;Lacas-Gervais S;Sheiko T;Pelletier J;Bourget I;Bost F;Féral C;Boulter E;Tauc M;Ivan M;Garmy-Susini B;Popa A;Mari B;Sarry JE;Craigen WJ;Pouysségur J;Mazure NM
通讯作者:
Mazure NM
影响因子:
4
作者:
Camara AKS;Zhou Y;Wen PC;Tajkhorshid E;Kwok WM
通讯作者:
Kwok WM
DOI:
10.1016/j.bbamcr.2016.01.019
发表时间:
2016-10-01
影响因子:
5.1
作者:
Colombini, Marco
通讯作者:
Colombini, Marco
影响因子:
4.3
作者:
Colombini, M
通讯作者:
Colombini, M
影响因子:
7.4
作者:
Bhat TA;Kumar S;Chaudhary AK;Yadav N;Chandra D
通讯作者:
Chandra D